Login / Signup

KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.

Vincenzo di PilatoNoemi AiezzaValentina ViaggiAlberto AntonelliLuigi PrincipeTommaso GianiFrancesco LuzzaroGian Maria Rossolini
Published in: Antimicrobial agents and chemotherapy (2020)
This study reports on the characterization of a Klebsiella pneumoniae clinical isolate showing high-level resistance to ceftazidime-avibactam associated with the production of KPC-53, a KPC-3 variant exhibiting a Leu167Glu168 duplication in the Ω-loop and a loss of carbapenemase activity. Whole-genome sequencing (WGS) revealed the presence of two copies of bla KPC-53, located on a pKpQIL-like plasmid and on a plasmid prophage of the Siphoviridae family, respectively. The present findings provide new insights into the mechanisms of resistance to ceftazidime-avibactam.
Keyphrases
  • klebsiella pneumoniae
  • escherichia coli
  • multidrug resistant
  • gram negative
  • drug resistant
  • crispr cas
  • transcription factor
  • single cell
  • pseudomonas aeruginosa